Phase 2Data readout

BGE-102

Obesity

BIOABioAge Labs

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: BGE-102
Development stage: Phase 2
Event type: Data readout
Indication: Obesity

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for BGE-102 in Obesity. The expected timing is based on the latest available company guidance and may change.

Development notes

5/29/25- Completed IND-enabling study. 8/15/25- Dosed first participant w/ SAD data by YE 2025 and topline data readout by YE 2026. 11/06/25:- Ph1 SAD/MAD trial underway with initial SAD data expected by year-end 2025. Company plans a proof-of-concept trial with topline data anticipated in H2 2026. 01/12/26:- Positive Ph1 MAD cohort data; full Ph1 data and Ph2a initiation in H1 2026, Ph2a data 2H 2026. 03/24/26:- Interim Ph1 obesity MAD data positive; full Ph1 and Ph2a start 1H 2026, Ph2a data 2H 2026. 04/21/26:- Full Ph1 dataset reported. Ph2 CV risk POC starts H1 2026; data H2 2026. Ph3 initiation targeted 2027. 05/08/26:- Ph1 showed large hsCRP reductions; Ph2 CV risk POC starts mid-2026, topline data by year-end 2026. 06/16/26:- First participant dosed in QUELL-CV Ph2 POC. Topline data expected H2 2026. 08/05/26:- QUELL-CV Ph2 design detailed; topline data expected H2 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

What is being tracked?

This catalyst tracks a Phase 2 data readout for BGE-102 in Obesity. The expected timing is based on the latest available company guidance and may change.